Overview
Dr. Wolf's research focuses on disordered mineral homeostasis across the spectrum of kidney disease. His team investigates the role of fibroblast growth factor 23 (FGF23) in normal phosphate and calcium homeostasis, its alterations in patients with chronic kidney disease, the adverse effects of excess FGF23 on cardiovascular health and the molecular mechanisms that underlie these risk relationships. He has consistently served as a principal investigator on National Institutes of Health (NIH) grants in basic and clinical research, epidemiology, and clinical trials.
Highlights
- 1
- 2The Journal of clinical endocrinology and metabolism · 2022
- 3Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
Publications
Funding
Active
2 grants- KPASN 255580-01Targeting CYP24A1 in the parathyroid glands as a novel treatment of secondary hyperparathyroidism in chronic kidney diseaseAmerican Society of Nephrology Inc · 2026–2028
- PIR01DK132060-03Tissue-Specific Regulation and Effects of CYP24A1National Institute of Diabetes and Digestive and Kidney Diseases · 2024–2027
Completed grants (10)
- Sub-PIUH3DK118748-06HiLo - Pragmatic trial of higher vs. lower serum phosphate targets in patients undergoing hemodialysisNational Institute of Diabetes and Digestive and Kidney Diseases · 2024–2024 · via Duke University
- PIR01DK076116-11Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney DiseaseNIDDK · 2007–2019 · via NIH RePORTER
- PIU01DK099930-04Pilot Studies Targeting Mineral Metabolism in Chronic Kidney DiseaseNIDDK · 2013–2018 · via NIH RePORTER
- PIK24DK093723-06Mentored Patient Oriented Research in Mineral MetabolismNIDDK · 2012–2017 · via NIH RePORTER
- PIR21DK100754-01A1FGF23 and mineral metabolism in Acute Kidney InjuryNIDDK · 2014–2016 · via NIH RePORTER
- PIK23RR017376-05Cardiovascular Disease Following Hypertensive PregnancyNCRR · 2003–2008 · via NIH RePORTER
- PIM01RR001066-31REDUCED PHOSPHATE INTAKE IN "NORMO-PHOSPHATEMIC" CHRONIC KIDNEY DISEASE PATIENTSNCRR · 2005–2008 · via NIH RePORTER
Honors & distinctions
- Member · Association of American Physicians
- Member · American Society for Clinical Investigation
News mentions
- Dr. Y. Michael Shim Named Chief of the Division of Pulmonary and Critical Care Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical CenterMarch 23, 2026
Dr. Y. Michael Shim, an esteemed physician-scientist who specializes in advanced pulmonary imaging and obstructive airway diseases, has been named chief of the Division of Pulmonary and Critical Care Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
- Dr. Judy Tung Named Chief of the Division of General Internal Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical CenterOctober 9, 2025
Dr. Judy Tung, a leading expert in internal medicine and primary care, has been named chief of the Division of General Internal Medicine in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective Aug. 1.
- Dr. Myles Wolf Appointed Chair of Medicine at Weill Cornell Medicine and Physician-in-Chief at NewYork-Presbyterian/Weill Cornell Medical CenterMay 13, 2024
Dr. Myles Wolf, an esteemed physician-scientist who specializes in nephrology, has been appointed chair of the Joan and Sanford I. Weill Department of Medicine at Weill Cornell Medicine and physician-in-chief at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 1.
External relationships
Leadership Roles
Akebia Therapeutics
Ownership
Akebia Therapeutics · Unicycive Therapeutics INC
Advisory/Scientific Board Member
Unicycive Therapeutics INC
Speaker/Lecturer
Pfizer, Inc.
Other
BridgeBio Pharma, Inc. · EvlaBio AG · Guidepoint Global LLC · Pharmacosmos Therapeutics Inc. · Vera Therapeutics INC